ImageneBio, Inc.

Deep Track Capital exited IMA last quarter, reducing specialist fund convergence to 5 remaining holders (BVF Partners, RTW Investments, OrbiMed Advisors, Boxer Capital). Deep Track's full exit is a notable negative signal given the firm's life sciences focus and typically high-conviction positioning — exits of this nature often reflect concerns around clinical execution, timeline slippage, or risk/reward deterioration relative to other opportunities. The continued presence of four other specialist funds provides some counterbalance, but the convergence thesis weakens meaningfully when a fund of Deep Track's caliber walks away entirely.

Unlock full AI analysis — 14-day free trial